117 related articles for article (PubMed ID: 21288582)
21. Tumour markers in chronic heart failure. Review of the literature and clinical implications.
Faggiano P; D'Aloia A; Antonini-Canterin F; Vizzardi E; Nicolosi GL; Cas LD
J Cardiovasc Med (Hagerstown); 2006 Aug; 7(8):573-9. PubMed ID: 16858234
[TBL] [Abstract][Full Text] [Related]
22. A hopeless case?
Woywodt A; Schneider G; Haller H; Hiss M
Nephrol Dial Transplant; 2007 Apr; 22(4):1253-6. PubMed ID: 17267542
[No Abstract] [Full Text] [Related]
23. Serum CA-125 level in end-stage renal disease patients maintained on chronic peritoneal dialysis or hemodialysis: the effect of continuous presence of peritoneal fluid, peritonitis, and peritoneal catheter implantation.
Bastani B; Chu N
Am J Nephrol; 1995; 15(6):468-72. PubMed ID: 8546167
[TBL] [Abstract][Full Text] [Related]
24. [How to start dialysis. Peritoneal dialysis--clinical aspects].
Quarello F
G Ital Nefrol; 2008; 25 Suppl 41():S25-6. PubMed ID: 18473316
[No Abstract] [Full Text] [Related]
25. Relationship between cytokines and tumour markers in patients with chronic heart failure.
Kosar F; Aksoy Y; Ozguntekin G; Ozerol I; Varol E
Eur J Heart Fail; 2006 May; 8(3):270-4. PubMed ID: 16309955
[TBL] [Abstract][Full Text] [Related]
26. CA 125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure.
Vizzardi E; Nodari S; D'Aloia A; Chiari E; Faggiano P; Metra M; Dei Cas L
Echocardiography; 2008 Oct; 25(9):955-60. PubMed ID: 18771557
[TBL] [Abstract][Full Text] [Related]
27. Peritoneal dialysis as a therapeutic approach in congestive heart failure resistant to pharmacological treatment.
Próchnicka A; Olszowska A; Baczyński D; Zelichowski G; Wańkowicz Z
Pol Arch Med Wewn; 2009 Dec; 119(12):815-9. PubMed ID: 20010468
[TBL] [Abstract][Full Text] [Related]
28. Circulating levels of carbohydrate antigen 125 in chronic heart failure: Useful or futile?
Morillas H; Núñez J; Moliner P
Eur J Heart Fail; 2024 Apr; 26(4):803-805. PubMed ID: 38562007
[No Abstract] [Full Text] [Related]
29. CA 125 levels and left ventricular function in patients with end-stage renal disease on maintenance hemodialysis.
Yilmaz H; Gürel OM; Celik HT; Sahiner E; Yildirim ME; Bilgiç MA; Bavbek N; Akcay A
Ren Fail; 2014 Mar; 36(2):210-6. PubMed ID: 24289262
[TBL] [Abstract][Full Text] [Related]
30. Conservative treatment of hydrothorax in a patient receiving peritoneal dialysis.
Pipili C; Kiousi E; Ntenta E; Vasileiou K; Grapsa E
Singapore Med J; 2017 Nov; 58(11):674-675. PubMed ID: 29167911
[No Abstract] [Full Text] [Related]
31. Prognostic value of pleural effusion, CA-125 and NT-proBNP in patients with acute decompensated heart failure.
Davutoglu V; Yildirim C; Kucukaslan H; Yuce M; Sari I; Tarakcioglu M; Akcay M; Cakici M; Ceylan N; Al B
Kardiol Pol; 2010 Jul; 68(7):771-8. PubMed ID: 20648434
[TBL] [Abstract][Full Text] [Related]
32. Serum tumor markers in patients on dialysis and kidney transplantation.
Lye WC; Tambyah P; Leong SO; Lee EJ
Adv Perit Dial; 1994; 10():109-11. PubMed ID: 7528056
[TBL] [Abstract][Full Text] [Related]
33. Peritoneal dialysis in patients with heart failure.
Van Der Sande FM; Cnossen TT; Cornelis T; Konings CJ; Kooman JP; Leunissen KM
Minerva Urol Nefrol; 2012 Sep; 64(3):163-72. PubMed ID: 22971681
[TBL] [Abstract][Full Text] [Related]
34. Hemodialysis vs. peritoneal dialysis in chronic heart failure: getting to the heart of the matter.
Pliquett RU; Girndt M
Kidney Int; 2012 Jun; 81(12):1274-5; author reply 1275. PubMed ID: 22648361
[No Abstract] [Full Text] [Related]
35. The lower risk of de novo heart failure associated with peritoneal dialysis; the timing does matter.
Kazory A
Int J Cardiol; 2017 Feb; 229():122. PubMed ID: 27825729
[No Abstract] [Full Text] [Related]
36. Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid.
Turk HM; Pekdemir H; Buyukberber S; Sevinc A; Camci C; Kocabas R; Tarakcioglu M; Buyukberber NM
Tumour Biol; 2003; 24(4):172-5. PubMed ID: 14654710
[TBL] [Abstract][Full Text] [Related]
37. Tumour biomarkers in heart failure: is there a role for CA-125?
Yilmaz MB; Nikolaou M; Cohen Solal A
Eur J Heart Fail; 2011 Jun; 13(6):579-83. PubMed ID: 21525015
[TBL] [Abstract][Full Text] [Related]
38. [The peritoneal ultrafiltration in patients with cardio-renal disease].
Corciulo R; Corciulo S
G Ital Nefrol; 2017 Mar; 34(Suppl 69):86-103. PubMed ID: 28682031
[TBL] [Abstract][Full Text] [Related]
39. [Peritoneal dialyisis role in heart failure treatment, experience in our center].
Díez Ojea B; Rodríguez Suárez C; Vidau P; Gago E; Díaz Molina B; Martín Fernández M; García Cueto C
Nefrologia; 2007; 27(5):605-11. PubMed ID: 18045037
[TBL] [Abstract][Full Text] [Related]
40. Lower risk of de novo congestive heart failure in peritoneal dialysis patients compared with hemodialysis patients.
Wang IK; Lin CL; Sung FC
Int J Cardiol; 2017 Feb; 229():123. PubMed ID: 27810291
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
